Trial · NCT05494788
Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)
NCT05494788, Phase 2, Completed, Cardiol Therapeutics Inc.; results first posted 2025-10-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot). Trials, record NCT05494788. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05494788
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)
- NCT number
- NCT05494788
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 27 participants, actual
- Lead sponsor
- Cardiol Therapeutics Inc.
- Conditions
- Recurrent Pericarditis
- Interventions
- CardiolRx
- First posted
- 2022-08-10
- Last updated
- 2025-10-20
- Results first posted
- 2025-10-20
- Limitations and caveats
In terms of limitations, this study was an open label, single-arm study so there was no control group. The number of patients included was also small but considered a sufficient sample size to demonstrate both the efficacy and safety objectives of this pilot study.
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 11-point NRS Pain Score | 8 weeks | Change in pain score from baseline using 11-point NRS after 8 weeks of treatment. Nominal Rating Scale from 0 to 10, where 0 represents no pain and 10 maximum pain. |
| Other | Pericarditis Recurrence During the Extension Period (EP) | 18 weeks | Percentage of patients with pericarditis recurrence during the extension period (EP) |
| Other | CRP Change From Baseline | 26 weeks | CRP change from baseline, as measured locally at baseline and at weeks 8, 16, and 26. |
| Other | Percentage of Patients With Normalized CRP Levels | 26 weeks | Percentage of patients with normalized CRP levels at 26 weeks (for patients with CRP ≥ 1.0 mg/dL at baseline) |
| Other | Percentage of Patients With Normalized CRP Levels | 8 weeks | Percentage of patients with normalized CRP levels at 8 weeks (for patients with CRP ≥1.0 mg/dL at baseline) |
| Other | Time to Normalized CRP Levels | Over 26 weeks | Time to CRP normalization for patients with CRP ≥1.0 mg/dL at baseline |
| Other | 11-point NRS Pain Score | 26 weeks | Change in pain score from baseline using 11-point NRS after 26 weeks of treatment. Nominal Rating Scale from 0 to 10, where 0 represents no pain and 10 maximum pain. |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 11-point NRS Pain Score | 8 weeks | All patients enrolled | units on a scale | MEAN |
| OTHER_PRE_SPECIFIED | Pericarditis Recurrence During the Extension Period (EP) | 18 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | CRP Change From Baseline | 26 weeks | mg/dl | MEAN | |
| OTHER_PRE_SPECIFIED | Percentage of Patients With Normalized CRP Levels | 26 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | Percentage of Patients With Normalized CRP Levels | 8 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | Time to Normalized CRP Levels | Over 26 weeks | days | MEAN | |
| OTHER_PRE_SPECIFIED | 11-point NRS Pain Score | 26 weeks | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group7
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 11-point NRS Pain Score | CardiolRx | -3.7 | Standard Deviation 2.07 | units on a scale | |
| Pericarditis Recurrence During the Extension Period (EP) | CardiolRx | 7 | Participants | ||
| CRP Change From Baseline | CardiolRx | 0.07 | Standard Deviation 0.10 | mg/dl | |
| Percentage of Patients With Normalized CRP Levels | CardiolRx | 7 | Participants | ||
| Percentage of Patients With Normalized CRP Levels | CardiolRx | 7 | Participants | ||
| Time to Normalized CRP Levels | CardiolRx | 26.4 | Standard Deviation 18.46 | days | |
| 11-point NRS Pain Score | CardiolRx | 4.3 | Standard Deviation 2.46 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Initial Treatment Period | STARTED | CardiolRx | 27 | |
| Initial Treatment Period | COMPLETED | CardiolRx | 24 | |
| Initial Treatment Period | NOT COMPLETED | CardiolRx | 3 | |
| Extension Period | STARTED | CardiolRx | 24 | |
| Extension Period | COMPLETED | CardiolRx | 22 | |
| Extension Period | NOT COMPLETED | CardiolRx | 2 |
Source ClinicalTrials.gov
Adverse events27
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Pericarditis | Cardiac disorders | CardiolRx | 8 | 27 | 10 |
| other | Abdominal discomfort | Gastrointestinal disorders | CardiolRx | 4 | 27 | 4 |
| other | Chest discomfort | General disorders | CardiolRx | 2 | 27 | 2 |
| other | COVID-19 | Infections and infestations | CardiolRx | 2 | 27 | 2 |
| other | INJURY, POISONING AND PROCEDURAL COMPLICATIONS | Injury, poisoning and procedural complications | CardiolRx | 3 | 27 | 3 |
| other | ALANINE AMINOTRANSFERASE INCREASED | Investigations | CardiolRx | 2 | 27 | 2 |
| other | METABOLISM AND NUTRITION DISORDERS | Metabolism and nutrition disorders | CardiolRx | 2 | 27 | 2 |
| other | Neck pain | Musculoskeletal and connective tissue disorders | CardiolRx | 2 | 27 | 2 |
| other | Headache | Nervous system disorders | CardiolRx | 4 | 27 | 4 |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | CardiolRx | 2 | 27 | 2 |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | CardiolRx | 0 | 27 |
| Total, other adverse events | CardiolRx | 14 | 27 |
| Total, serious adverse events | CardiolRx | 1 | 27 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05494788
GET https://conductscience.org/api/trials/v1/NCT05494788/events?page=2